

# Angela Lamarca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2249067/publications.pdf>

Version: 2024-02-01

116  
papers

4,855  
citations

172457

29  
h-index

106344

65  
g-index

118  
all docs

118  
docs citations

118  
times ranked

4490  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	17.8	1,155
2	New Horizons for Precision Medicine in Biliary Tract Cancers. <i>Cancer Discovery</i> , 2017, 7, 943-962.	9.4	419
3	Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2021, 22, 690-701.	10.7	396
4	Second-line chemotherapy in advanced biliary cancer: a systematic review. <i>Annals of Oncology</i> , 2014, 25, 2328-2338.	1.2	279
5	Molecular targeted therapies: Ready for prime time in biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 170-185.	3.7	226
6	Clinical presentation, diagnosis and staging of cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 98-107.	3.9	171
7	ABC-06   A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4003-4003.	1.6	166
8	HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 141-157.	5.9	119
9	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. <i>Journal of Hepatology</i> , 2022, 76, 1109-1121.	3.7	119
10	Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2020, 112, 200-210.	6.3	90
11	Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis. <i>Journal of Clinical Medicine</i> , 2020, 9, 273.	2.4	89
12	<sup>18</sup> F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 115-129.	3.7	76
13	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. <i>Cancer Treatment Reviews</i> , 2020, 84, 101936.	7.7	73
14	Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020, 16, 2375-2384.	2.4	62
15	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. <i>Cancer Treatment Reviews</i> , 2020, 89, 102084.	7.7	61
16	Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers. <i>Journal of Clinical Medicine</i> , 2020, 9, 2854.	2.4	61
17	Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. <i>Cancer Treatment Reviews</i> , 2018, 70, 168-177.	7.7	55
18	Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2571-2580.	1.6	49

#	ARTICLE	IF	CITATIONS
19	Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1035-1043.e2.	0.5	49
20	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). <i>Journal of Clinical Oncology</i> , 2021, 39, 2304-2312.	1.6	49
21	Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?. <i>Cancer Treatment Reviews</i> , 2016, 44, 26-41.	7.7	45
22	Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102258.	7.7	45
23	How I treat biliary tract cancer. <i>ESMO Open</i> , 2022, 7, 100378.	4.5	45
24	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. <i>Hepatology</i> , 2021, 73, 2311-2325.	7.3	40
25	Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 723-731.	3.0	37
26	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. <i>British Journal of Cancer</i> , 2020, 123, 1047-1059.	6.4	37
27	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. <i>Scientific Reports</i> , 2019, 9, 11610.	3.3	36
28	High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2020, 110, 891-898.	2.5	34
29	Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours. <i>Clinical and Translational Oncology</i> , 2017, 19, 579-586.	2.4	32
30	Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw277.	6.3	28
31	Telotristat ethyl: a new option for the management of carcinoid syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2487-2498.	1.8	27
32	Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET) – The GREPONET Study. <i>Oncologist</i> , 2019, 24, e1082-e1090.	3.7	26
33	Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. <i>European Journal of Cancer</i> , 2015, 51, 1694-1703.	2.8	25
34	Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103328.	4.4	25
35	Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. <i>British Journal of Cancer</i> , 2018, 118, 181-188.	6.4	23
36	Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. <i>World Journal of Gastroenterology</i> , 2016, 22, 6065.	3.3	23

#	ARTICLE	IF	CITATIONS
37	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 909.	4.1	21
38	Clinical and Translational Research Challenges in Biliary Tract Cancers. <i>Current Medicinal Chemistry</i> , 2020, 27, 4756-4777.	2.4	21
39	Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 1999-2019.	7.0	20
40	Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study. <i>Clinical Cancer Research</i> , 2019, 25, 6692-6699.	7.0	18
41	Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy. <i>British Journal of Cancer</i> , 2022, 126, 693-705.	6.4	18
42	Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma. <i>Current Oncology Reports</i> , 2017, 19, 50.	4.0	17
43	Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review. <i>Neuroendocrinology</i> , 2021, 111, 354-369.	2.5	17
44	The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 3779.	3.7	16
45	Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer. <i>Chinese Clinical Oncology</i> , 2019, 8, 43-43.	1.2	16
46	<sup>68</sup> Gallium DOTANOC-PET Imaging in Lung Carcinoids: Impact on Patients' Management. <i>Neuroendocrinology</i> , 2018, 106, 128-138.	2.5	15
47	Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. <i>ESMO Open</i> , 2021, 6, 100104.	4.5	15
48	The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. <i>PLoS ONE</i> , 2018, 13, e0206007.	2.5	14
49	Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery. <i>Surgical Oncology</i> , 2016, 25, 223-228.	1.6	13
50	Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 1682-1688.	1.1	13
51	Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). <i>Cancers</i> , 2020, 12, 1988.	3.7	12
52	Current and New Biomarkers for Early Detection, Prognostic Stratification, and Management of Gallbladder Cancer Patients. <i>Cancers</i> , 2020, 12, 3670.	3.7	12
53	The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-standard. <i>Pancreatology</i> , 2020, 20, 668-675.	1.1	12
54	Safety, tolerability and clinical implementation of a "ready-to-use" <sup>68</sup> Gallium-DOTA0-Tyr3-octreotide ( <sup>68</sup> Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). <i>ESMO Open</i> , 2020, 5, e000650.	4.5	12

#	ARTICLE	IF	CITATIONS
55	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). <i>BMI Open</i> , 2020, 10, e034527.	1.9	11
56	Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. <i>Gut</i> , 2022, , gutjnl-2022-327099.	12.1	11
57	Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3616-3627.	3.6	10
58	18F-FLT PET imaging of cellular proliferation in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 158-169.	4.4	10
59	Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice. <i>Journal of Clinical Medicine</i> , 2019, 8, 1630.	2.4	10
60	Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. <i>Endocrine-Related Cancer</i> , 2021, 28, 549-561.	3.1	10
61	Prevalence of symptomatic pancreatic exocrine insufficiency in patients with pancreatic malignancy: nutritional intervention may improve survival. <i>Cancer Research Frontiers</i> , 2016, 2, 352-367.	0.2	10
62	Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry. <i>Cancers</i> , 2022, 14, 2389.	3.7	10
63	Abc-06: a Randomised Phase Iii, Multi-Centre, Open-Label Study of Active Symptom Control (Asc) Alone or Asc with Oxaliplatin / 5-Fu Chemotherapy for Patients with Locally Advanced / Metastatic Biliary Tract Cancers (Abc) Previously Treated with Cisplatin / Gemcitabine Chemotherapy.. <i>Annals of Oncology</i> , 2014, 25, iv252.	1.2	9
64	Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). <i>Clinical and Translational Oncology</i> , 2019, 21, 950-953.	2.4	9
65	Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2358-2371.	6.4	9
66	Temozolomide-Capcitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration. <i>Neuroendocrinology</i> , 2020, 110, 155-157.	2.5	8
67	Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2248-2255.	1.0	8
68	Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>ESMO Open</i> , 2022, 7, 100377.	4.5	8
69	Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability. <i>Neuroendocrinology</i> , 2021, 111, 831-839.	2.5	7
70	Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 975-983.	4.1	7
71	The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2020, 38, e16686-e16686.	1.6	7
72	Targeted Therapies for Perihilar Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 1789.	3.7	7

#	ARTICLE	IF	CITATIONS
73	Identification of Areas for Improvement in the Management of Bone Metastases in Patients with Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2020, 110, 688-696.	2.5	6
74	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 94, 102168.	7.7	6
75	Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. <i>Current Treatment Options in Oncology</i> , 2021, 22, 73.	3.0	6
76	Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes. <i>Oncologist</i> , 2022, 27, 97-103.	3.7	6
77	Fibrolamellar carcinoma: Challenging the challenge. <i>European Journal of Cancer</i> , 2020, 137, 144-147.	2.8	5
78	Outcomes in older patients with biliary tract cancer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 569-575.	1.0	5
79	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 377-388.	4.1	5
80	Ivosidenib: an investigational drug for the treatment of biliary tract cancers. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 301-307.	4.1	5
81	Clinical and Translational Research Challenges in Neuroendocrine Tumours. <i>Current Medicinal Chemistry</i> , 2020, 27, 4823-4839.	2.4	5
82	Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: A systematic review and meta-analysis. <i>Annals of Oncology</i> , 2019, 30, v25.	1.2	4
83	HPB cancers in older patients   inclusion of older/senior patients in clinical trials. <i>European Journal of Surgical Oncology</i> , 2021, 47, 597-602.	1.0	4
84	Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?. <i>Cancers</i> , 2021, 13, 4152.	3.7	4
85	Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1073-1085.	2.0	4
86	The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2021, 10, 403.	2.4	4
87	Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours. <i>World Journal of Clinical Oncology</i> , 2020, 11, 205-216.	2.3	4
88	Pancreatic Enzyme Replacement Therapy for Patients Diagnosed With Pancreaticobiliary Cancer. <i>Pancreas</i> , 2021, 50, 1254-1259.	1.1	4
89	Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy. <i>Acta OncolÁgica</i> , 2022, 61, 583-590.	1.8	4
90	<p>Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7537-7556.	1.9	3

#	ARTICLE	IF	CITATIONS
91	In the literature: June 2019. ESMO Open, 2019, 4, e000547.	4.5	3
92	Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3 <sup>rd</sup> -line treatment. World Journal of Gastroenterology, 2021, 27, 976-989.	3.3	3
93	Should Patients with Resected Bile Duct Cancer Receive an Adjuvant Treatment?. The Journal of Oncopathology, 2014, 2, 57-68.	0.1	3
94	Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 101, 102299.	7.7	3
95	Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. European Journal of Surgical Oncology, 2022, 48, 1198-1208.	1.0	3
96	Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply. Lancet Oncology, The, 2021, 22, e288-e289.	10.7	2
97	REPLY:. Hepatology, 2021, 74, 1129-1131.	7.3	2
98	Pilot, proof-of-concept studies for determining the feasibility of the use of FLT-PET in patients with pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, TPS4146-TPS4146.	1.6	2
99	Looking Beyond Chemotherapy in Patients with Advanced, Well-differentiated, Pancreatic Neuroendocrine Tumors. The Journal of Oncopathology, 2014, 2, 15-25.	0.1	2
100	Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World Journal of Gastrointestinal Oncology, 2019, 11, 102-116.	2.0	2
101	Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice. Cancers, 2022, 14, 1017.	3.7	2
102	Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies. Expert Review of Anticancer Therapy, 2022, 22, 1009-1015.	2.4	2
103	Reply to the letter to the editor –Second-line chemotherapy in advanced biliary cancer: the present now will later be past™ by Vivaldi et al.. Annals of Oncology, 2014, 25, 2444-2445.	1.2	1
104	Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the study of cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging. Annals of Oncology, 2019, 30, v280-v281.	1.2	1
105	FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?. ESMO Open, 2020, 5, e000633.	4.5	1
106	Reaching out beyond first-line treatments in advanced biliary tract cancers. Annals of Oncology, 2020, 31, 1099-1102.	1.2	1
107	PD-1 Systematic review and meta-analysis of the efficacy of chemotherapeutic regimens in advanced gallbladder cancer: Assessing current practice and treatment benefit. Annals of Oncology, 2020, 31, S212.	1.2	1
108	REPLY:. Hepatology, 2021, 74, 2319-2321.	7.3	1

#	ARTICLE	IF	CITATIONS
109	Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence. Endocrine Abstracts, 0, , .	0.0	1
110	Unusual skull base metastasis from neuroendocrine tumor: a case report. Journal of Medical Case Reports, 2019, 13, 273.	0.8	0
111	Systemic therapies in elderly patients with advanced hepatocellular carcinoma: do not forget metronomic capecitabine. European Journal of Surgical Oncology, 2021, 47, 2209-2210.	1.0	0
112	Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).. Journal of Clinical Oncology, 2021, 39, 348-348.	1.6	0
113	Molecular profiling of advanced pancreatic ductal adenocarcinoma (PDAC): Role of ctDNA.. Journal of Clinical Oncology, 2021, 39, 425-425.	1.6	0
114	Latest advances in cholangiocarcinoma. Liver Cancer International, 0, , .	1.3	0
115	RELEVANT study: Patient (Pt) and physician (PI) perspectives on meaningful outcomes in advanced pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2020, 38, 150-150.	1.6	0
116	Work-Up and Outcome of Hepatic Resection for Peri-Hilar Cholangiocarcinoma (PH-CCA) without Staging Laparoscopy. Cancers, 2022, 14, 1841.	3.7	0